Filing Flows › Comparisons › LCTX vs TCRX
Lineage Cell Therapeutics vs TScan Therapeutics: LCTX and TCRX compared
Lineage Cell Therapeutics is the larger company: $1.1M of revenue in its latest quarter (Q2 2026) against $1.1M for TScan Therapeutics (Q2 2026). Lineage Cell Therapeutics is growing faster (-61% against -66% a year earlier).
Where the money goes: LCTX and TCRX
Lineage Cell Therapeutics (LCTX) · Q2 2026
Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
TScan Therapeutics (TCRX) · Q2 2026
TScan Therapeutics, Q2 2026: revenue $1.1M (-66% year over year), net loss $30.4M, operating cash flow −$27.5M. The chart follows the revenue to costs, profit and cash.
| Lineage Cell Therapeutics (LCTX) | TScan Therapeutics (TCRX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $1.1M | $1.1M |
| Revenue growth, Y/Y | -61% | -66% |
| Operating margin | -834.7% | n/m |
| Net earnings | $1.5M | −$30.4M |
| Net margin | 144.4% | — |
| Operating cash flow | −$7.2M | −$27.5M |
Where the revenue comes from
Lineage Cell Therapeutics
- Collaboration Revenues: $943K (88%)
- Royalties License and Other Revenues: $126K (12%)
Questions
Which is bigger, Lineage Cell Therapeutics or TScan Therapeutics?
Lineage Cell Therapeutics is the larger company: $1.1M of revenue in its latest quarter (Q2 2026) against $1.1M for TScan Therapeutics (Q2 2026).
Is Lineage Cell Therapeutics or TScan Therapeutics growing faster?
Lineage Cell Therapeutics is growing faster (-61% against -66% a year earlier).
More: Lineage Cell Therapeutics earnings · how Lineage Cell Therapeutics makes money · TScan Therapeutics earnings · how TScan Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.